Ozempic and Kidney Health: Is Semaglutide Safe for Your Kidneys? (SA Guide 2026)
Kidney disease is a serious and growing health concern in South Africa, affecting an estimated 10-15% of the adult population to some degree. For many South Africans on Ozempic (semaglutide) or considering it, a critical question arises: what does this medication do to my kidneys?
The answer is surprisingly reassuring — and increasingly backed by strong evidence. Far from harming kidney function, semaglutide appears to actively protect it. Here's what the science says.
How the Kidneys and Obesity Are Connected
The kidneys are remarkably sensitive to the metabolic effects of excess weight. Obesity drives kidney damage through several pathways:
- Hypertension: High blood pressure from obesity directly strains the kidney's filtration vessels
- Insulin resistance: Leads to elevated blood sugar, which glycates (damages) kidney filtration membranes
- Increased intraglomerular pressure: Excess weight forces the kidneys to filter more blood per minute, straining the glomeruli
- Inflammation: Adipose tissue releases inflammatory cytokines that damage kidney cells
- Hyperlipidaemia: Elevated cholesterol deposits in kidney vasculature
South Africa has among the highest rates of obesity, hypertension, and type 2 diabetes in sub-Saharan Africa — all major risk factors for chronic kidney disease (CKD). Effective weight loss treatment is therefore critically important for kidney health in the South African population.
What the Research Shows About Semaglutide and Kidneys
The FLOW Trial (2024): A Landmark Result
The FLOW trial enrolled over 3,500 adults with type 2 diabetes and CKD (eGFR 50-75 ml/min/1.73m²). Participants received either weekly semaglutide 1 mg or placebo. The trial was stopped early because the results were so clearly positive for semaglutide. Compared to placebo:
- 24% reduction in major kidney events (kidney failure, 50% decline in eGFR, kidney death)
- 18% relative reduction in annual eGFR decline rate
- Significant reduction in urinary albumin-to-creatinine ratio (a key marker of kidney damage)
- Lower rates of cardiovascular events (important since CKD and heart disease are closely linked)
The SELECT Trial (2023)
In the SELECT trial studying semaglutide in people with cardiovascular disease (without diabetes), participants using semaglutide showed significantly better kidney outcomes than those on placebo, adding evidence that the kidney-protective effects extend beyond diabetes management alone.
How Does Semaglutide Protect the Kidneys?
Researchers believe the kidney-protective effects come through multiple mechanisms:
| Mechanism | What It Means |
|---|---|
| Weight reduction | Less body mass = lower intraglomerular pressure and kidney workload |
| Blood pressure lowering | Reduced hypertension = less strain on kidney vessels |
| Blood sugar control | Lower glucose = less glycation damage to kidney membranes |
| Direct GLP-1 receptor activation | GLP-1 receptors on kidney cells may have anti-inflammatory, anti-fibrotic effects |
| Reduced albuminuria | Less protein leaks into urine, indicating better filtration membrane integrity |
| Anti-inflammatory effects | Systemically lower inflammation reduces kidney cell damage |
Who Should Be Cautious?
While the news is largely positive, some situations require extra care:
Dehydration Risk
Ozempic's GI side effects (nausea, vomiting, diarrhoea) can cause significant fluid loss. Dehydration is a real cause of acute kidney injury (AKI) in Ozempic users. If you're experiencing severe GI symptoms, prioritise hydration and contact your doctor.
Severe CKD (Stage 4-5)
People with severely impaired kidney function (eGFR below 30 ml/min) were largely excluded from trials. Use caution and require specialist supervision in this group.
Contrast Dye Procedures
If you're scheduled for a procedure using iodinated contrast dye (CT scans, angiography), your doctor may temporarily pause semaglutide due to combined risk of contrast nephropathy in already-slow gut motility situations.
The Context for South Africa
South Africa faces a dual burden: very high rates of obesity and metabolic disease driving CKD, alongside limited nephrology specialist capacity. Many South Africans reach dialysis or advanced kidney failure before being detected. GLP-1 medications like Ozempic represent one of the most powerful tools available to intercept the obesity-to-kidney-disease pathway earlier.
The South African Society of Nephrology and the South African Diabetes Association have both begun incorporating GLP-1 receptor agonists into their guidance for patients with both obesity/diabetes and CKD, following the FLOW trial results.
Managing Obesity-Related Conditions
Kidney health is just one reason weight matters. Explore our guide to Ozempic for diabetes and metabolic health.
Ozempic and Diabetes: SA GuideBottom Line
For the vast majority of South Africans considering or currently using Ozempic, the kidney news is good. Semaglutide is not a kidney hazard — it is emerging as one of the most kidney-protective medications available for people with obesity and metabolic disease. The main kidney-related risk (dehydration from GI side effects) is manageable with awareness and adequate fluid intake.
If you have existing CKD, discuss Ozempic with your nephrologist. The evidence increasingly suggests it may be one of the best things you can do for your kidneys — not despite having kidney disease, but because of it.